U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07423481) titled 'Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity' on Feb. 13.
Brief Summary: SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY(R) (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.
Study Start Date: June 01, 2026
Study Type: OBSERVATIONAL
Condition:
Obesity & Overweight
Intervention:
OTHER: SEMAFOLLOW quest...